|
|
Vaccine Detail
|
Ovarian Tumor Antigen-activated Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Ovarian Tumor Antigen-activated Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007133
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- JUP
gene engineering:
- ITGB8
gene engineering:
- DDR1
gene engineering:
- Preparation: Naturally processed HLA-A2 restricted peptides presented by breast, ovarian and prostate cancer cells were used as antigens to create a therapeutic cancer vaccine (Berinstein et al., 2012).
- Description: This is for Ovarian Cancer(NCT02107950). A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with an ovarian tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the ovarian tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells expressing ovarian tumor cell-specific antigens, which may result in ovarian tumor cell lysis (Berinstein et al., 2012; NCIT_C115105).
|
| Host Response |
|
|
| References |
Berinstein et al., 2012: Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Journal of translational medicine. 2012; 10; 156. [PubMed: 22862954].
NCIT_C115105: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115105]
NCT02107950: [https://clinicaltrials.gov/ct2/show/NCT02107950]
|
|
